An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
WALTHAM, Mass.--(BUSINESS WIRE)--
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the hiring of Kelley Dealhoy, Senior Vice President and Chief Business Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 100,000 shares of Deciphera’s common stock and 45,000 restricted stock units (“RSUs”) to Ms. Dealhoy with a grant date of July 15, 2022.
The equity awards were granted under the Company’s 2022 Inducement Plan and were made pursuant to Nasdaq Listing Rule 5635(c)(4). The grants were an inducement material to Ms. Dealhoy accepting employment with the Company. The options have a ten-year term, and the exercise price of the options is $13.01, equal to the fair market value of the Company’s common stock on the Nasdaq on July 15, 2022. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Ms. Dealhoy’s date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-third of the shares underlying 25,000 of the RSUs will vest annually over a three-year period beginning on or about the one-year anniversary of the grant date. A grant of 20,000 RSUs will vest in full on or about the one-year anniversary of the grant date. The awards are subject to the terms and conditions of their applicable equity award agreements, including having a continued relationship with the Company on the vesting date.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
